PYPD שווי מלא של הפעילות העסקית PolyPid Ltd.

Market fluctuations in PolyPid Ltd. (PYPD) shares on GURU.Markets reflect an enterprise value of 102.25, supported by patent protection for slow-release antibiotic delivery systems and entry into profitable distribution channels. The business relies on the PLEX method for targeted wound treatment, minimizing the risk of complications. This segment possesses exceptional crisis resilience, as surgery remains in demand regardless of economic conditions.

Investments in the development of drug delivery systems require an assessment of all PolyPid Ltd. resources. This indicator aggregates market capitalization and net debt, excluding cash and cash equivalents. By analyzing the enterprise value, an investor sees the actual price for a full buyout of the business. This allows for an evaluation of the capital intensity of the chemists' and engineers' research. The final issuer profile reveals the true scale of the company without market distortions.